LDN-212320
CAS No. 894002-50-7
LDN-212320( LDN/OSU-0212320 | LDN-0212320 | OSU-0212320 )
Catalog No. M26737 CAS No. 894002-50-7
LDN-212320 is a glutamate transporter EAAT2 activator. It also enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 35 | Get Quote |
|
| 5MG | 58 | Get Quote |
|
| 10MG | 88 | Get Quote |
|
| 25MG | 178 | Get Quote |
|
| 50MG | 336 | Get Quote |
|
| 100MG | 504 | Get Quote |
|
| 500MG | 1071 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLDN-212320
-
NoteResearch use only, not for human use.
-
Brief DescriptionLDN-212320 is a glutamate transporter EAAT2 activator. It also enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.
-
DescriptionLDN-212320 is a glutamate transporter EAAT2 activator. It also enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.(In Vitro):LDN/OSU-0212320 enhanced EAAT2 protein levels and glutamate uptake function but did not affect EAAT1 or EAAT3 protein levels and it also increased EAAT2 protein levels in a dose-dependent (EC50: 1.83 ± 0.27 μM) and time-dependent manner. LDN/OSU-0212320 treatment markedly prevented neuronal loss and degeneration, as assessed by MAP2 immunostaining .(In Vivo):After LDN/OSU-0212320(a single i.p.; 40-mg/kg) treatment, EAAT2 protein levels and associated glutamate uptake increased by approximately 1.5- to 2-fold at 2 hours and by approximately 2- to 3-fold between 8 and 24 hours after injection. Even 72 hours after injection, an approximately 1.5-fold increase in EAAT2 protein levels could still be detected (data not shown). LDN/OSU-0212320–induced EAAT2 protein levels and glutamate uptake was dose-dependent .
-
In Vitro——
-
In VivoLDN-212320 (10 or 20 mg/kg, i.p) significantly attenuates formalin-evoked nociceptive behavior. LDN-212320 (10 or 20 mg/kg, i.p) significantly reverses formalin-induced impaired hippocampal-dependent behavior. In addition, LDN-212320 (10 or 20 mg/kg, i.p) increases GLT-1 expressions in the hippocampus and ACC.LDN-212320 (20 mg/kg, i.p) significantly reduced formalin induced-ERK phosphorylation, a marker of nociception, in the hippocampus and ACC. Animal Model:Mice.Dosage:10 or 20 mg/kg.Administration:IP 24 h before the injection of formalin.Result:Significantly attenuated licking and biting behavior during both phases 1 and 2 in a dose-dependent manner compared to formalin-injected mice.Significantly (P < 0.01 or P < 0.001) reduced the licking and biting behavior.Significantly increased preference for the displaced object (F3, 13 = 28.03, P < 0.01) compared to formalin-injected mice.Significantly (P < 0.001) increased interaction time with the displaced object compared to formalin-injected mice.
-
SynonymsLDN/OSU-0212320 | LDN-0212320 | OSU-0212320
-
PathwayOthers
-
TargetOther Targets
-
RecptorNK2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number894002-50-7
-
Formula Weight293.39
-
Molecular FormulaC17H15N3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (170.42 mM)
-
SMILESCc1ccccc1CSc1ccc(nn1)-c1ccccn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Pluck G. Preliminary Validation of a Free-to-Use, Brief Assessment of Adult Intelligence for Research Purposes: The Matrix Matching Test. Psychol Rep. 2018 Jan 1:33294118762589.
molnova catalog
related products
-
Ebopiprant
Ebopiprant (OBE022) is an orally available, selective and potent prostaglandin F2α (PGF2α) receptor antagonist that interferes with the binding of PGF0126α to the FPR and can be used in the study of obesity.
-
Scoparin
Scoparin has antioxidant activity.Scoparin has antibacterial activity.
-
11-Deoxyalisol A
The tubers of Alisma plantago-aquatica Linn.
Cart
sales@molnova.com